Published in Curr Eye Res on September 01, 1991
Allergic conjunctivitis exacerbates corneal allograft rejection by activating Th1 and th2 alloimmune responses. J Immunol (2010) 0.97
Corneal transplantation and immune privilege. Int Rev Immunol (2013) 0.91
Immunology of Corneal Allografts: Insights from Animal Models. J Clin Exp Ophthalmol (2015) 0.79
IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol (2009) 2.65
Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness. Proc Natl Acad Sci U S A (2000) 2.60
Epithelial injury induces keratocyte apoptosis: hypothesized role for the interleukin-1 system in the modulation of corneal tissue organization and wound healing. Exp Eye Res (1996) 2.25
Clinical and diagnostic use of in vivo confocal microscopy in patients with corneal disease. Ophthalmology (1993) 1.64
Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med (1981) 1.63
Oral immunisation as a strategy for enhancing corneal allograft survival. Br J Ophthalmol (1997) 1.51
Proinflammatory chemokine induction in keratocytes and inflammatory cell infiltration into the cornea. Invest Ophthalmol Vis Sci (2001) 1.50
Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea. Exp Eye Res (1994) 1.46
Spontaneous corneal neovascularization in nude mice. Local imbalance between angiogenic and anti-angiogenic factors. Invest Ophthalmol Vis Sci (1993) 1.41
Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol (1998) 1.40
Resistance of Acanthamoeba castellanii cysts to physical, chemical, and radiological conditions. J Parasitol (2002) 1.40
Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J Immunol (1985) 1.38
Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci (1991) 1.34
A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol (1998) 1.30
Effect of epidermal growth factor, hepatocyte growth factor, and keratinocyte growth factor, on proliferation, motility and differentiation of human corneal epithelial cells. Exp Eye Res (1994) 1.27
Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). Immunology (1998) 1.23
Effect of steroids on Acanthamoeba cysts and trophozoites. Invest Ophthalmol Vis Sci (2001) 1.21
In vivo and in vitro collagenolytic activity of Acanthamoeba castellanii. Invest Ophthalmol Vis Sci (1990) 1.21
Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens. J Exp Med (1980) 1.21
Ocular disease induced in mice by anterior chamber inoculation of herpes simplex virus. Invest Ophthalmol Vis Sci (1984) 1.19
Role of antibody and complement in the control of Encephalitozoon cuniculi infections by rabbit macrophages. Infect Immun (1980) 1.19
In vitro and in vivo tumoricidal properties of a pathogenic/free-living amoeba. Cancer Lett (1993) 1.19
Mannose induces the release of cytopathic factors from Acanthamoeba castellanii. Infect Immun (1998) 1.17
Hepatocyte growth factor, keratinocyte growth factor, their receptors, fibroblast growth factor receptor-2, and the cells of the cornea. Invest Ophthalmol Vis Sci (1993) 1.14
Susceptibility of corneas from various animal species to in vitro binding and invasion by Acanthamoeba castellanii [corrected]. Invest Ophthalmol Vis Sci (1992) 1.12
Expression of E6/E7 or SV40 large T antigen-coding oncogenes in human corneal endothelial cells indicates regulated high-proliferative capacity. Invest Ophthalmol Vis Sci (1995) 1.11
Gamma delta T cells are needed for ocular immune privilege and corneal graft survival. J Immunol (2001) 1.10
The role of macrophages in Acanthamoeba keratitis. Invest Ophthalmol Vis Sci (1996) 1.08
EGF, EGF receptor, basic FGF, TGF beta-1, and IL-1 alpha mRNA in human corneal epithelial cells and stromal fibroblasts. Invest Ophthalmol Vis Sci (1992) 1.08
Antigenic cross-reactivity among different microsporidan spores as determined by immunofluorescence. J Parasitol (1980) 1.06
Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci (1995) 1.05
The role of contact lenses, trauma, and Langerhans cells in a Chinese hamster model of Acanthamoeba keratitis. Invest Ophthalmol Vis Sci (1993) 1.04
Susceptibility of selected inbred strains of mice to Encephalitozoon cuniculi. J Infect Dis (1981) 1.04
Extended life of human corneal endothelial cells transfected with the SV40 large T antigen. Invest Ophthalmol Vis Sci (1993) 1.04
Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol (2000) 1.03
Characterization and pathogenic potential of a soil isolate and an ocular isolate of Acanthamoeba castellanii in relation to Acanthamoeba keratitis. Curr Eye Res (1992) 1.03
Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol (1987) 1.03
Identification of a locus for disseminated superficial actinic porokeratosis at chromosome 12q23.2-24.1. J Invest Dermatol (2000) 1.03
Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses. J Immunol (1983) 1.02
Apoptosis as a mechanism of cytolysis of tumor cells by a pathogenic free-living amoeba. Infect Immun (1994) 1.02
Intracameral inoculation of herpes simplex virus type I induces anterior chamber associated immune deviation. Curr Eye Res (1983) 0.99
Analysis of antibody production induced by allogeneic tumor cells inoculated into the anterior chamber of the eye. Transplantation (1982) 0.99
EGF, basic FGF, and TGF beta-1 messenger RNA production in rabbit corneal epithelial cells. Invest Ophthalmol Vis Sci (1992) 0.98
Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1. J Immunol (2001) 0.98
The effect of oral immunization on corneal allograft survival. Transplantation (1996) 0.97
Acanthamoeba keratitis. CLAO J (1995) 0.96
Tear IgA and serum IgG antibodies against Acanthamoeba in patients with Acanthamoeba keratitis. Cornea (2001) 0.96
Characterization of a plasminogen activator produced by Acanthamoeba castellanii. Mol Biochem Parasitol (1995) 0.95
The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest Ophthalmol Vis Sci (2000) 0.95
The diagnosis and management of Acanthamoeba keratitis. CLAO J (2000) 0.94
Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol (2010) 0.93
A pig model of Acanthamoeba keratitis: transmission via contaminated contact lenses. Invest Ophthalmol Vis Sci (1992) 0.93
Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol (1996) 0.93
Role of mucosal IgA in the resistance to Acanthamoeba keratitis. Invest Ophthalmol Vis Sci (1998) 0.93
Role of Th1 and Th2 cells in anterior chamber-associated immune deviation. Immunology (1996) 0.93
Systemic immune response to Acanthamoeba keratitis in the Chinese hamster. Ocul Immunol Inflamm (1997) 0.92
In vitro characterization of Acanthamoeba castellanii cytopathic effect. J Parasitol (1995) 0.91
Immunologic evaluation of spontaneous regression of an intraocular murine melanoma. Invest Ophthalmol Vis Sci (1990) 0.90
IFN-γ blocks CD4+CD25+ Tregs and abolishes immune privilege of minor histocompatibility mismatched corneal allografts. Am J Transplant (2013) 0.90
Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci (1999) 0.90
Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology (1995) 0.90
Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci (1997) 0.89
Angiostatin produced by certain primary uveal melanoma cell lines impedes the development of liver metastases. Arch Ophthalmol (2001) 0.89
Spontaneous immune rejection of intraocular tumors in mice. Invest Ophthalmol Vis Sci (1985) 0.89
Expression of HLA class I and II antigens on cells of the human trabecular meshwork. Ophthalmology (1987) 0.89
Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res (1995) 0.88
Antibody-dependent neutrophil-mediated killing of Acanthamoeba castellanii. Int J Parasitol (1994) 0.88
Glucocorticoid receptor and interleukin-1 receptor messenger RNA expression in corneal cells. Cornea (1994) 0.87
Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival. Invest Ophthalmol Vis Sci (1994) 0.87
Heterotopic corneal grafting in mice: a new approach to the study of corneal alloimmunity. Invest Ophthalmol Vis Sci (1982) 0.87
The presence of donor-derived class II-positive cells abolishes immune privilege in the anterior chamber of the eye. Transplantation (1991) 0.87
Immunogenetic basis for immunologic privilege in the anterior chamber of the eye. Immunogenetics (1981) 0.86
Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases. J Immunol (1982) 0.86
Association between NM23-H1 gene expression and metastasis of human uveal melanoma in an animal model. Invest Ophthalmol Vis Sci (1996) 0.86
Characterization of intraocular tumors arising in transgenic mice. Invest Ophthalmol Vis Sci (1994) 0.86
Enhanced natural killer cell activity in experimental murine encephalitozoonosis. Infect Immun (1983) 0.86
Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea (1996) 0.86
Successful immunization against Acanthamoeba keratitis in a pig model. Cornea (1995) 0.86
Characteristics of rejection of orthotopic corneal allografts in the rat. Transplantation (1988) 0.86
Chemotactic response of macrophages to Acanthamoeba castellanii antigen and antibody-dependent macrophage-mediated killing of the parasite. J Parasitol (1992) 0.86
Oral immunization with Acanthamoeba castellanii mannose-binding protein ameliorates amoebic keratitis. Infect Immun (2006) 0.85
Suppressed cellular immunity in mice harboring intraocular melanomas. Invest Ophthalmol Vis Sci (1984) 0.84
Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye. Cancer Immunol Immunother (1990) 0.84
Monoclonal IgA antibodies protect against Acanthamoeba keratitis. Exp Eye Res (1999) 0.84
Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. J Immunol (1983) 0.84
Alloantigen presentation to the anterior chamber of the eye subverts specific in vitro cell-mediated immune responses. Transplantation (1982) 0.83
Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. Invest Ophthalmol Vis Sci (1998) 0.83
The differential effects of donor versus host Langerhans cells in the rejection of MHC-matched corneal allografts. Transplantation (1991) 0.83
Enucleation in consort with immunologic impairment promotes metastasis of intraocular melanomas in mice. Invest Ophthalmol Vis Sci (1984) 0.82
Aqueous humor-borne factor upregulates Bcl-2 expression in corneal endothelial cells. Curr Eye Res (1998) 0.81
T cell subsets in the immune rejection of murine heterotopic corneal allografts. Invest Ophthalmol Vis Sci (1986) 0.81
Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice. Invest Ophthalmol Vis Sci (1995) 0.81
Capacity of simian virus 40 T antigen to induce self-tolerance but not immunological privilege in the anterior chamber of the eye. Transplantation (1994) 0.81
In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber. Immunology (1991) 0.81
Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr Eye Res (1994) 0.81
Allergic conjunctivitis renders CD4(+) T cells resistant to t regulatory cells and exacerbates corneal allograft rejection. Am J Transplant (2013) 0.80